Company

Silk Road Medical, Inc.

Silk Road Medical develops and manufactures the TCAR System, a device for transcarotid access to treat carotid artery disease.

About

Silk Road Medical's TCAR System combines transcarotid access with reverse flow to optimize stent placement during carotid artery disease treatment. Founded in 2007 and based in Sunnyvale, US, the company is at the Series C stage. In June 2024 Boston Scientific Corporation agreed to acquire it from CRG, Janus Henderson Investors, Norwest Venture Partners, Vertical Group and Warburg Pincus for USD 1.16 billion, with closing expected in H2 2024. Chas McKhann is CEO.

8Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in